Valley Health System and Inbound Health have joined forces to launch a “Hospital at Home” programme.
Slated to commence this summer, the initiative aims to provide “high-acuity” inpatient care to the eligible individuals within their homes.
Go deeper with GlobalData
It is designed to manage common inpatient diagnoses including pneumonia, congestive heart failure, and cellulitis.
Valley Health noted that, hospital-at-home programmes have been receiving traction nationally, amid the aging US population and chronic conditions.
These programmes are said to have demonstrated their potential in minimising hospital readmissions and enhancing outcomes for patients.
To qualify for the Hospital at Home programme, individuals need to visit The Valley Hospital, where their medical condition and home environment will be evaluated for safety.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataFollowing this assessment, patients may be referred to the Hospital at Home programme if they meet the necessary criteria.
Once enrolled, patients in the programme will benefit from daily clinical assessments, medical supplies, round-the-clock monitoring, and home visits from healthcare professionals.
Valley Health System CEO and president Robert Brenner said: “Valley is pleased to partner with Inbound Health to bring hospital-level care to our patients where they feel most comfortable – at home.
“This programme reflects our strategic commitment to making care more flexible, personal, and compassionate. With Hospital at Home, we are extending the trusted care our community expects from Valley beyond the hospital’s walls, offering safe, high-quality services where they’re needed most.”
The collaboration with Inbound Health will utilise virtual and in-market care teams, logistics, technology, and clinical protocols to support safe care delivery outside the traditional hospital setting.
This April, the Valley Hospital performed its first implant of the Food and Drug Administration (FDA)-approved Evoque tricuspid valve replacement system by Edwards Lifesciences.
Meanwhile, in 2023, Inbound Health secured $30m in a Series B financing round, led by HealthQuest Capital.
